AbCellera (ABCL): Among the Stocks That Could 10x Over the Next 5 Years

AbCellera Biologics Inc. (NASDAQ:ABCL) ranks among the stocks that could 10x over the next 5 years. On March 17, AbCellera Biologics Inc. (NASDAQ:ABCL) outlined its vision at the KeyBanc Capital Markets Healthcare Forum 2026, emphasizing its transition to a mid- to late-stage biotech with significant drug discovery capabilities.

The company boasted a strong financial position, with around $700 million in cash and a three-year runway supported by government funding. Its annual cash burn of $120 to $130 million also funds early-stage development across many programs.

The AbCellera Biologics Inc. (NASDAQ:ABCL) pipeline is also in focus, which includes ABCL635, currently in Phase 2 trials for the non-hormonal treatment of hot flashes, with potential development into cancer-related applications. ABCL575 is in Phase 1 testing for immunological diseases, with plans for further collaborations.

Meanwhile, on February 24, AbCellera Biologics Inc. (NASDAQ:ABCL) announced earnings per share of -0.03, compared to an expected loss of $0.18, reflecting an 83.33% earnings outperformance.

Its revenue climbed by $39.80 million over the previous year. The fourth-quarter results came after a difficult third quarter in 2025, when ABCL missed earnings per share projections by $0.02.

AbCellera Biologics Inc. (NASDAQ:ABCL) discovers and develops antibody-based medicines for indications with unmet medical needs in the US.

While we acknowledge the risk and potential of ABCL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABCL and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years. 

Disclosure: None. Follow Insider Monkey on Google News.